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14. ASSOCIATION BETWEEN PLASMA
HOMOCYSTEINE, VITAMIN STATUS, AND
EXTRACRANIAL CAROTID-ARTERY
STENOSIS IN THE FRAMINGHAM STUDY
POPULATION

Jacob Selhub, Paul F. Jacques, Andrew G. Bostom, Ralph B. D'Agostino,
Peter W.F. Wilson, Albert J. Belanger, Daniel H. O'Leary, Philip A. Wolf, David Rush,
Ernst J. Schaefer, and Irwin H. Rosenberg

Summary
Recent epidemiologic studies suggest that elevated
homocysteine concentrations in plasma represent a
risk factor for vascular disease and stroke. In the
present study, we analyzed plasma samples from the
20th biannual examination of the Framingham Heart
Study cohort to determine distribution of plasma
homocysteine concentrations, with emphasis on
relationships to vitamins that are involved in
homocysteine metabolism and prevalence of carotid
artery stenosis. Results showed that homocysteine
was positively correlated with age. After controlling
for age and sex, homocysteine exhibited strong
inverse correlation with plasma folate, and weaker
correlations with plasma vitamin Bl2 and pyridoxal5' -phosphate. Homocysteine was also inversely correlated with intakes of folate and vitamin B6 , but not
vitamin B l2 • Prevalence of high homocysteine
(>14~mol!L) was 29.3% in this cohort, and
inadequate plasma concentrations of one or more
B vitamins appeared to contribute to 67% of the
cases of high homocysteine. After adjustment for
sex, age, HDL cholesterol, systolic blood pressute,
and cigarette smoking, the prevalence of carotidartery stenosis ~25% was 43% in men and 34%
in women with an odds ratio of 2.0 for individuals
in the highest homocysteine quartile, compared
with those in the lowest quartile (p < 0.001).
Plasma concentrations of folate and pyridoxal-

5' -phosphate and folate intake were inversely associated with extracranial carotid stenosis after adjustment for age, sex, and other risk factors. These data
indicate that hyperhomocysteinemia is prevalent
(30%) in this aged population, and that it is associated with increased risk of extracranial carotid-artery
stenosis. Insufficient levels of folate, and, to a lesser
extent, vitamin B6 , appear to predict part of this
elevated risk through their role in homocysteine
metabolism.

Introduction
In recent years, there have been· growing indications
suggesting that moderate elevations of homocysteine
in plasma are a risk factor for occlusive vascular disease and stroke [l-3J. A literature survey by Ueland
et al. [1 J identified a total of 21 studies involving
more than 1,500 patients with occlusive (cardiovascular, peripheral, and cerebrovascular) vascular disease
and more than 1,500 respective controls. Sixteen of
these studies reported significantly higher mean
plasma homocysteine concentrations in patients than
in respective controls (p < 0.05 to < 0.001). The mean
patient/control homocysteine ratio according to this
survey was 1.31, which indicates that the elevation
of homocysteine in these patients is mild and certainly not as severe as that seen in homocystinuric
patients.
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FIGURE 14-1. Homocysteine metabolism: 1, methylene-

Our interest in homocysteine was prompted by the
possibility that plasma homocysteine may serve as an
indicator of the status and perhaps the intake of a
number of vitamins, including folic acid, vitamin B 12 ,
and vitamin B6 • This possibility derived from the
large number of studies indicating that methionine
metabolism is tightly regulated [4-6}, and from
other studies showing that deficiencies in the above
vitamins is often associated with hyperhomocysteinemia [7-20}.
Homocysteine is a sulfur amino acid whose metabolism is at the intersection of two metabolic pathways: remethylation and transsulfuration (fig. 14-1).
In remethylation, homocysteine acquires a methyl
group from N-5-methyltetrahydrofolate (MTHF) or
from betaine to form methionine. The reaction with
MTHF occurs in all tissues and is vitamin B I2 -depen-

tetrahydrofolate reductase; 2, cystathionine-~-synthase; 3,
cystathionase; THF, tetrahydrofolate; PLP, pyridoxal-5'phosphate; and CH3-Bw methylated vitamin B12 •

dent, while the reaction with betaine is confined
mainly to the liver and is vitamin B I2 -independent. A
considerable proportion of methionine is then activated by ATP to form S-adenosylmethionine (SAM).
SAM serves primarily as a universal methyl donor to
a variety of acceptors, including guanidinoacetate,
nucleic acids, neurotransmitters, phospholipids, and
hormones. S-adenosylhomocysteine (SAH), the byproduct of these methylation reactions, is subsequently hydrolyzed, thus regenerating homocysteine,
which then becomes available to start a new cycle of
methyl-group transfer.
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In the transsulfuration pathway, homocysteine
condenses with serine to form cystathionine in an
irreversible reaction catalyzed by the pyridoxal- 5'phosphate (PLP)-containing enzyme, cystathionine
~-synthase. Cystathionine is hydrolyzed by a second
PLP-containing enzyme, y-cystathionase, to form cysteine and a-ketobutyrate. Excess cysteine is oxidized
to taurine and inorganic sulfates or excreted in the
urine. Thus, in addition to the synthesis of cysteine,
this transsulfuration pathway effectively catabolizes
excess homocysteine that is not required for methyl
transfer. It is important to note that since homocysteine is not a normal dietary constituent, the sole
source of homocysteine is methionine.
Studies of the regulation of homocysteine metabolism have demonstrated that the utilization of
homocysteine molecules by the transsulfuration and
remethylation pathways is nutritionally regulated.
Mudd and Poole (21J and Mudd et al. (22J have
shown that when the intake of labile methyl groups
(i.e., methionine and choline) is modified, the de novo
synthesis of methionine methyl groups is affected.
When a basal methionine-containing diet was fed,
homocysteine moieties were found to cycle through
the remethylation pathway approximately 1.5 to
2.0 times before being catabolized through the
transsulfuration pathway. When dietary methionine
was halved, the number of cycles per homocysteine
moiety increased twofold. Conversely, when excess
dietary methionine was fed, homocysteine cycling
decreased below basal levels. Similar adaptations to
changing levels of dietary methionine were observed
by Eloranta et al. in rats (23].
This capacity of the body to discriminate between
the remethylation and transsulfuration pathways as a
way to adapt to varying amounts of methionine in the
diet strongly implies the existence of a coordinate
regulation between these two pathways. Available
experimental evidence, obtained primarily from measurements of enzyme activities in vitro, suggests that
this coordination is achieved by at least two mechanisms. The first mechanism is a function of SAM's
propensity to act as an allosteric inhibitor of
methylenetetrahyrofolate reductase (24J and as an
activator of cystathionine ~-synthase (25]. As such an
effector, SAM suppresses the synthesis of an important substrate (N-5-methyltetrahydrofolate) required
for remethylation and promotes the initial reaction of
transsulfuration (cystathionine synthesis). Thus, intracellular SAM concentration is an important determinant of the fate of homocysteine molecules.
The second mechanism by which remethylation
and transsulfuration are coordinated consists of the
regulation of intracellular SAM concentration itself.
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In the liver, SAM synthesis is catalyzed by two enzymes that are peculiar to this organ and that,
although immunologically similar, are different in
other respects (26-27]. One enzyme, a tetramer of
high molecular weight, exhibits a high affinity for
methionine and is thought to function at normal
physiologic conditions. The second enzyme is a dimer
of a lower molecular weight, has a low affinity for
methionine, and is thought to function under conditions of high methionine intake. Thus, changes in
intracellular methionine, particularly due to dietary
intake, will affect the rate of SAM synthesis based on
the activity of the SAM synthetase enzymes.
The utilization of SAM also is thought to be regulated specifically by a reaction in which the methyl
group of SAM is transferred to the amino group of
glycine, forming sarcosine. This reaction is catalyzed
by glycine N-methyltransferase (GNMT), which is
abundant in the liver and which is strongly inhibited
by N-5-methyltetrahydrofolate polyglutamates (2930]. Thus, along with intracellular methionine, N-5methyltetrahydrofolate participates in the regulation
of intracellular SAM concentrations.
When the two mechanisms of regulation are considered together, the following scenarios can be
predicted:
1. When dietary methionine is high, the low
molecular weight SAM synthetase will rapidly
convert the incoming methionine to SAM. The
resulting rise in intracellular SAM concentration will be associated with: a) inhibition of
methylenetetrahydrofolate reductase, resulting in
suppressed N-5-methyltetrahydrofolate synthesis,
thereby allowing the GNMT enzyme to act near
full capacity because of suppressed inhibitor (N-5methyltetrahydrofolate) concentration, and b) activation of the cystathionine ~-synthase enzyme,
thus increasing the rate of homocysteine catabolism. In this way, homocysteine transsulfuration is
promoted over remethylation consistent with the
reduced need for de novo methionine synthesis
due to the high dietary supply of methionine.
2. Conversely, when the dietary methionine supply
is low, SAM concentration would be insufficient
for inhibiting methylenetetrahydrofolate reductase, resulting in an elevated rate of N-5methyltetrahydrofolate production. The resulting
rise in intracellular N-5-methyltetrahydrofolate
concentration will be associated with: a) inhibition of GNMT and thereby conservation of SAM,
and b) an increase in the availability of substrate
for homocysteine remethylation. Thus, remethylation will be favored over transsulfuration because
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of a concentration of SAM too low to activate the
cystathionine ~-synthase enzyme. This is consistent with the increased need for de novo methionine synthesis because of the low dietary input of
methionine.
Due to the existence of a cellular homocysteine
export mechanism, plasma normally contains a small
amount of homocysteine, averaging 10 J..LmollL
[31,22}. This export mechanism complements the
catabolism of homocysteine through transsulfuration; together these mechanisms help maintain low
intracellular concentrations of this potentially cytotoxic sulfur amino acid. In hyperhomocysteinemia,
plasma homocysteine levels are elevated. Barring
kidney malfunction, the occurrence of hyperhomocysteinemia indicates that homocysteine metabolism
has in some way been disrupted and that the export
mechanism is disposing excess homocysteine into
the blood that has accumulated in the cell. This
limits intracellular toxicity, but leaves vascular tissue
exposed to the possibly deleterious effects of excess
homocysteine.
The aims of our study were therefore to: (1) to
determine the relationship between plasma homocysteine concentrations and status and intake of
folate, vitamin BI2 and vitamin B6; (2) to determine
the prevalence of hyperhomocysteinemia; (3) to
determine the contribution of vitamin status and
intake to the prevalence of hyperhomocysteinemia
and; (4) to describe the associations between
plasma homocysteine, vitamin status, and intake
and prevalence of carotid artery stenosis. This chapter
IS a summary of our two previous publications
[33,34}.

Methods
SUBJECTS

Participants were members of the original
Framingham Heart Study cohort, a population-based
sample of 5 ,209 men and women originally examined
in 1948-1952 [35} and followed prospectively to the
present to assess the occurrence of vascular disease.
This study was based on 1,401 survivors of the
original cohort who participated in the 20th biennial
examination (1989-1990). Homocysteine and carotid
ultrasound measures were available for 1,041 individuals (418 men and 623 women) 67-96 years of age
at the time of data collection. Informed consent was
obtained from all participants. The protocols for this
study were approved by the Human Investigations
Review Committee at New England Medical Center

and by the Institutional Review Board for Human
Research at Boston University Medical Center.
BIOCHEMICAL DETERMINATIONS

Blood was drawn nonfasting, and plasma total cholesterol and HDL cholesterol were determined in the
Framingham Heart Study laboratory using enzymatic
methods [36,37J. LDL cholesterol was not determined because the blood samples were taken in a
nonfasting state. Plasma samples stored frozen at
-80°C were used for the determination of total
homocysteine by the method of Araki and Sako [38},
plasma folate was determined by a microbial assay
using a 96-well plate and manganese supplementation as described by Tamura et al. [39}, vitamin BI2
using a (Magic) radioassay kit from Ciba-Corning
(Medfield, MA), and pyridoxal-5f-phosphate by the
tyrosine decarboxylase method as described by
Camp et al. [40}. Because of insufficient plasma
volume, vitamin measures were not available for all
subjects.
NUTRIENT INTAKE

Members of the Framingham cohort received a
semiquantitative food frequency questionnaire by
mail [31} when they were scheduled for their 20th
biennial examination. Subjects returned the completed questionnaire at the time of their examination.
Estimated folate and vitamin B6 intakes corresponded
well to the respective folate and PLP plasma concentrations. Vitamin BI2 intake was not, however, correlated with plasma vitamin B12 [31,32}.
MEASUREMENT OF CAROTID STENOSIS

At the 20th biennial examination, participants
underwent a carotid Doppler examination with
Ultrasonix, high resolution, real-time scanner
equipped with a 7.5MHz imaging transducer, a 4MHz pulse wave Doppler transducer, and a 4-MHz
continuous wave transducer. For this report, we classified individuals into two categories based on the maximum percent diameter stenosis of the more diseased
artery: 0%-24% stenosis or 25%-100% stenosis.
STATISTICAL METHODS

To describe the assocIatIOns between plasma
homocysteine concentrations and the B vitamins, we
grouped subjects into deciles of plasma vitamin concentration and vitamin intake. We calculated the
geometric mean plasma homocysteine concentrations
in each vitamin decile and plotted these values and
their 95% confidence limits at the median vitamin
level within each decile. We adjusted mean homocysteine levels for age, sex, and concentration or intake of the other B vitamins by analysis of covariance
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[43J, with all covariates set to their respective sample
means. We also adjusted all vitamin intakes for energy [44].
To examine the association between the occurrence
of high plasma homocysteine concentrations and
these vitamins, we defined high homocysteine as concentrations >14.0 IlmollL (the 90th percentile for
homocysteine among those subjects whose three
plasma vitamins levels were above the 70th percentile). We developed a B-vitamin index to describe the
joint relationships of the three vitamins included in
these analyses to homocysteine levels. The indices had
five categories based on percentile values for each
nutrient. We classified individuals with all three vitamins above the 70th percentile into the reference
category (category 1). Category 2 included individuals with all three vitamins above the 50th but at least
one below the 70th percentile; category 3 included
those with at least one vitamin above and one vitamin
below the 50th percentile; category 4 included those
with all three vitamins below the 50th percentile but
at least one above the 30th percentile; and category 5
included individuals with all vitamins below the 30th
percentile. We determined mean homocysteine concentration, the prevalence of high homocysteine, the
prevalence rate ratio for high homocysteine, and attributable proportion (attributable risk percent [45])
within each vitamin index category. We also estimated population attributable proportion, which
represents the proportion of cases with high homocysteine in the population that can be attributed to
low plasma vitamin concentrations or vitamin intake.
To graphically describe the relation of homocysteine to stenosis, we classified men and women
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into quartiles of homocysteine concentration. Within
each quartile, we computed the prevalence of carotid
stenosis 2::25% and plotted the prevalence estimates
at the sex-specific median homocysteine concentration for that quartile. To adjust for other risk factors
for carotid stenosis, logistic regression was used
with stenosis 2::25% as the dependent variable.
Homocysteine quartiles were modeled using indicator variables to represent the three highest quartiles,
and relative risk of stenosis for each quartile, compared with the lowest quartile, was estimated as the
odds ratio derived as the antilogarithm of the logistic
regression coefficients. To examine the association
between the nutrition determinants of plasma
homocysteine and stenosis, we also divided subjects
into quartiles for each vitamin measure and represented them in the regression models as indicator
variables using the highest plasma vitamin quartile as
the reference category to estimate the relative risk of
lower nutrient levels. If not otherwise noted, statistical significance refers to P less than 0.05.

Results
HOMOCYSTEINE DISTRIBUTION
AND PREVALENCE OF HIGH
HOMOCYSTEINE CONCENTRATIONS

The mean homocysteine concentration for all subjects
was 11.91lmollL (median = 11.6IlmollL). Values
ranged ftom 3.5 to 66.9IlmollL. Homocysteine concentration was higher in men than in women and
increased with age (table 14-1). The increase with age
remained highly significant (P < 0.001) for men and

TABLE 14-l. Mean homocysteine and B vitamin status and intake by age and sex
Plasma concentrations

Sex

Age, y n

Homocysteine,
IlmollL

& Elevated

Folate,
nmollL

Vitamin
B12 pmollL

PLP
nmollL

Folate,
Ilg

Vitamin
B 12 llg

Vitamin
B6mg

Men

67-74
75-79
80+

11.8
11.9
14.1

25.3
26.7
48.3

9.3
9.5
10.0

265
260
255

52.6
49.6
47.6

174
180
204

3.7
3.8
4.8

1.4

<0.001

<0.001

0.02

0.81

10.7
11.9
13.2

19.5
28.9
41.4

4.0
4.4
4.9

1.6
1.5
1.5

by age)

<0.001

<0.001

0.60

0.47

0.13

0.23

0.Q3

0.55

P (sex)

0.003

0.09

0.19

0.001

0.08

<0.001

0.07

0.02

239
110
108

Homocysteine,

Nutrient intake/4,200KJ

1.3

1.4

P (for trend

by age)
Women

67-74
75-79
80+

310
204
189

0.41
10.4
10.2
9.7

0.62
302
289
290

0.36
59.9
52.2
52.1

0.02
214
220
199

P (for trend
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women after adjustment for plasma vitamin concentrations, but the difference between men and women
was no longer statistically significant.
We defined high homocysteine as concentrations
greater than the 90th percentile among subjects
with all plasma vitamin levels >70th percentile
(14.0IlmollL). Prevalence of high homocysteine was
29.3% for the entire cohort and over 40% for individuals SO years of age and older.

Mean Homocysteine Concentration by
Vitamin Status and Intake

10.11lmollL (fig. 14-3c). Subjects in the lowest three
intake deciles reported consuming less than 1. 7 5 mg/
day.

Homocysteine Concentrations by Overall
Vitamin Status
Mean homocysteine and the prevalence of high
homocysteine increased dramatically across categories of the B-vitamin index (table 14-2). Mean
homocysteine concentration was 75% greater in the
lowest relative to the highest index categories. The

FOLATE

Mean plasma homocysteine concentrations for subjects in the two lowest deciles of plasma folate (below
4.SnmollL) were 15.6 and 13.7IlmollL. These were
significantly greater than the mean for subjects in the
highest decile, which was 11.0 IlmollL (p < 0.01) (fig.
14-2A). Mean homocysteine concentrations for subjects in the three lowest deciles of folate intake (less
than 253Ilg/day) were 13.7, 12.9, and 13.2IlmollL,
respectively, and were significantly greater than the
mean for subjects in the highest intake decile, which
was lO.4llmollL (p < 0.01) (fig. 13-3A).

a

18
16
14
12
10
8
0

Mean homocysteine concentrations were significantly
elevated for subjects in the lowest decile for vitamin
B 12 relative to subjects in the highest decile (p <
0.01). Mean homocysteine concentrations were 15.4
and 10.91lmollL for subjects in the lowest and highest vitamin Bl2 deciles (fig. 14-2B). Subjects in the
lowest vitamin B12 decile had vitamin Bl2 concentrations below 139pmollL. Vitamin Bl2 intake appeared
unrelated to mean homocysteine concentration even
though subjects in the fifth decile had significantly
higher homocysteine concentrations than subjects in
the highest decile (p < 0.05) (fig. 13-3B).
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Mean homocysteine concentrations were significantly
elevated for subjects in the lowest decile for PLP
relative to subjects in the highest decile for this vitamin (p < 0.01). Mean homocysteine concentrations
were 14.3 and 10.91lmollL for subjects in the lowest
and highest PLP deciles (fig. 14-2c). Subjects in
the lowest decile and PLP concentrations below
lS.l nmollL. For vitamin B6 intake, mean homocysteine concentrations were significantly elevated in
the lowest two deciles (p < 0.01) and the third decile
(p < 0.05). Mean homocysteine concentrations were
13.4, 12.4, and 12.31lmollL for subjects in the lowest
three deciles; the mean in the highest decile was
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FIGURE 14-2. Mean plasma homocysteine concentrations
(and 95% confidence intervals) by deciles of plasma folate
(a), vitamin B12 (b) and PLP (c) concentrations. Means
are adjusted for age, sex and other plasma vitamins. (* significantly different from mean in the highest decile {p <
0.01].)
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TABLE 14-2. Elevated homocysteine concentrations by B vitamin status

n

Mean
homocysteine
(flmollL)

2
3
4

89
128
534
144

5

70

B vitamin
I
Index
Highest

Lowest

(%)

Prevalence
rate
ratio

Attributable
percent

Population
attributable
percent

9.4
9.8
11.9*
14.9*

10.1
12.5
28.7*
52.1 *

1.2
2.8
5.2

0.0
19.2
64.8
80.6

0.0
1.0
33.7
20.6

16.5*

58.6*

5.8

82.8
(total)

66.9

Prevalence

11.6

I Index combines plasma folate, vitamin B12 and PLP concentrations: High (1) = all three B vitamins> 70th percentile; 2 = all vitamins> 50th, at least 1 <
70th percentile; 3 = vitamins above and below the 50th percentile; 4 = all vitamins < 50th percentile. at least 1 > 30th percentile; low (5) = all three vitamins
< 30th percentile.
• Significantly different from category I (P < 0.0l).
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prevalence of high homocysteine was almost sixfold
greater among subjects in the lowest index category,
compared with subjects in the highest category for
plasma index. Sixty-seven percent of the cases of high
homocysteine in this cohort of older subjects were
associated with at least one vitamin concentration
below the 70th percentile. Although the prevalence
of high homocysteine was substantially greater in
lower vitamin categories (4 and 5) than in the middle
category, this latter category contributed the largest
share of cases of high homocysteine for the index,
because it included the largest proportion of the
cohort.

Relationship Between Plasma Homocysteine
and Prevalence of Extracranial Stenosis
The prevalence of extracranial carotid stenosis ~25%
was approximately 43% and 34% in men and women,
respectively. Fig. 14-4 shows the age-adjusted prevalence of stenosis across quartiles of plasma
homocysteine levels. In men, the prevalence of
stenosis ~25 percent was 27% (95% confidence interval [l7%-38%}) in the lowest homocysteine quartile
and 58% (95% confidence interval [49%-67%} in
the highest quartiles (p < 0.001). The correlation in
women was not as striking as that in men; prevalence
of stenosis ~25% ranged from 31 % (95% confidence
interval (24-38%» to 39% (95% confidence interval,
(31-47%» across homocysteine quartiles (p= 0.03).
While the risk of stenosis appeared to increase in
the second homocysteine quartile (9.1-11.3 flmoll
liter) among men, it did not appear to increase until
the third homocysteine quartile (1l.4-14.3 flmoll
liter) among women. Although the prevalence of
stenosis appeared somewhat greater among men than
women in the upper quartiles of homocysteine, a test
of interaction between sex and homocysteine indicated that the trends for prevalence of stenosis ~25%

were not significantly different for men and women
(p = 0.07).

The age- and sex-adjusted odds ratios (OR) for men
and women combined were significantly increased in
the third (OR =l.6; 95% confidence interval [l.12.4}) and fourth (OR = 2.1; 95% confidence interval
[l.5-3.0}) quartiles of homocysteine (~14.4flmoll
liter) relative to the lowest quartile (:5:9.1 flmolliiter)
(table 14-3). Adjustment for other risk factors had
little effect on the ORs.
The associations between carotid stenosis and the
plasma vitamins are shown in table 14-4. The prevalence of stenosis ~25% was inversely associated with
both folate (P"end < 0.001) and pyridoxal-5'-phosphate (P mnd = 0.03) after adjustment for age, sex, and
other risk factors. The OR for stenosis was l.9 (95%
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FIGURE 14-4. Age-adjusted prevalence and 95% confidence limits of maximum extracranial carotid artery diameter stenosis ;0:25% by quartile of plasma homocysteine
concentration in men (squares) and women (circles).
Homocysteine quartile cutoff values were 9.1, 11.3, and
14.3I1moliliter. Test for linear trend: P < 0.001 for men,
P = 0.03 for women.

TABLE 14-3. Odds ratio of maximal extracranial carotid artery diameter
stenosis ;0:25% by quartile of plasma homocysteine concentration (n = 1,041)

Age and sex adjusted

Multiple risk factor adjustment!

Homocysteine
quartile (I1moliL)

Odds ratio

95% CIt

P-value

::;9.1
9.2-11.3
11.4-14.3
;0:14.4

1.0
1.1
1.6
2.1

0.8, 1.6
1.1, 2.4
1.5, 3.0

0.60
0.009
<0.001
<0.001

Ptrend

t

CI = confidence interval.

~ Adjusted for sex, age, totallHDL cholesterol ratio, smoking status, and systolic blood pressure.

Odds Ratio

95% CI

P-value

1.0
1.1
1.6
2.0

0.8, 1.6
1.1, 2.3
1.4, 2.9

0.58
0.02
<0.001
<0.001
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TABLE 14-4. Odds ratios of maximal extracranial carotid artery diameter stenosis ~25% by quartile of plasma vitamins

Multiple risk factor adjustment!
Vitamin

N

Folate (~g/L)
<2.51
2.51-4.31
4.32-7.92

1,027

~7.93

P rrend
Vitamin B12 (ng/L)
<290
290-405
406-572

Odds ratio

95% CI*

P-value

1.9
1.4
1.2
1.0

1.3, 2.7
1.0,2.0
0.8, 1.8

0.001
0.08
0.28

95% CI

P-value

1.5

1.0, 2.3
0.9, 1.9
0.8, 1.8

0.04
0.24
0.35

1.3
1.2
1.0

<0.001
1.4
1.4

1.3

0.9,2.1
0.9,2.0
0.9,2.0

0.11
0.14
0.16

1.0

0.05
1.2
1.2
1.3
1.0

0.8, 1.8
0.8, 1.8
0.9, 1.9

0.11

P trend

~89.81

Odds ratio

881

~573

Pyridoxal-5 f -phosphate (nmol/L)
<31.91
31.91-52.19
52.20-89.80

Multiple risk factor adjustment
plus homocysteine

0.41
0.36
0.24
0.47

967
1.6
1.1
1.2
1.0

Ptrend

1.1, 2.4
0.7, 1.6
0.8, 1.7

0.02
0.67
0.48

1.3
1.0
1.1
1.0

0.9,2.0
0.6, 1.4
0.7, 1.6

0.03

0.15
0.80
0.71
0.23

= confidence interval.
Adjusted for sex, age, totallHDL cholesterol ratio, smoking status, and systolic blood pressure.
~ To convert to SI units, multiply folate values by 2.266 to get values in nmollL and vitamin B12 values by 0.7378 to get values in pmollL.

* CI
t

confidence interval [l.3-2.7}) in the lowest folate
quartile and l.6 (95% confidence interval [l.1-2.4})
in the lowest pyridoxal-5' -phosphate quartile. Plasma
vitamin B12 exhibited a weak association with stenosis
(P mnd = 0.11). The OR for stenosis was 1.4 (95%
confidence interval [0.9-2.1} in the lowest vitamin
B12 quartile compared with the highest quartile. Adjustment for homocysteine diminished the strength
of plasma vitamin associations, but the elevated
prevalence of stenosis in the lowest plasma folate
quartile remained evident (OR: l.5; 95% confidence
interval: l.0-2.3).

Discussion
These data suggest an important role for nutntIon
in homocysteine metabolism. We have demonstrated
strong, nonlinear, inverse associations between
homocysteine concentrations and plasma concentrations of folate, vitamin B 12 , and vitamin B6 • We observed that individuals with low levels of each of these
vitamins had high plasma homocysteine concentrations, while those with moderate vitamin levels had
dramatically lower homocysteine concentrations.
Homocysteine levels did not differ substantially between individuals with moderate and high vitamin
concentrations.

The results for folate and vitamin B6 intake data are
consistent with those for the plasma vitamins. Although it is risky to attribute discrete quantitative
values based on this method of dietary assessment
[41}, it still may be worth noting that homocysteine
concentrations were elevated among individuals with
folate intakes up to 280 flg/day, which is higher than
the current RDA of 200 and 180 flg/day for adult
men and women, and vitamin B6 intakes as high as
l.92 mg/day, which is less than the RDA of 2.0 mgl
day for men but greater than the RDA of l.6mg/day
for women.
Adequate levels of all three vitamins may be
needed to obtain an optimal homocysteine concentration. Using the index based on levels of all three
vitamins, we estimated that approximately twothirds of the cases of elevated homocysteine concentration in this cohort were associated with low or
moderate plasma levels of one or more of the three
vitamins.
Our data also provide evidence that plasma
homocysteine levels are associated with extracranial
carotid stenosis in a population-based, elderly cohort.
We observed that risk of stenosis ;::::25 % was increased
at homocysteine concentrations previously believed to
be normal, based on levels of homocysteine among
normative samples. As in our previous analysis, we
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defined elevated plasma homocysteine as concentrations >14 ~mol/L (90th percentile among individuals
with apparently adequate folate, vitamin B12 and
vitamin B6 status). Stampfer et al. [46} defined
elevated homocysteine as concentrations greater than
15.8 ~mol/liter (95th percentile among nondiseased
control subjects). Joosten et al. [47} defined elevated
homocysteine as concentrations greater than
13.9 ~mol/L (mean plus two standard deviations
among healthy young controls). Genest and coworkers [48} reported 90th and 95th percentile values of
15.0 and 19.0~mol/L among their normal controls.
In the present study we observed that risk of stenosis
was elevated at levels of homocysteine between 11.4
and 14.3 ~mol/L. These data will require us to reconsider the current beliefs regarding standards for
elevated homocysteine.
We have also examined the relations between specific nutrition determinants of hyperhomocysteinemia and stenosis in this elderly cohort. We further
demonstrated that folate and pyridoxal-5' -phosphate
were linked to stenosis, in large part, due to their
regulation of plasma homocysteine levels as indicated
by the diminished odds ratios between stenosis and
these vitamins after adjustment for homocysteine levels. Although there was some residual association between plasma folate and stenosis after adjustment for
homocysteine, the likelihood ratio test statistic would
suggest that addition of folate to a model containing
homocysteine did not add any significant contribution. It is likely that measurement error and biologic
variability -in both folate and homocysteine might
explain the residual folate association.
We demonstrated that the majority of these elderly
individuals with elevated homocysteine concentrations have insufficient status of folate, vitamin B12 , or
vitamin B6, and that others have demonstrated that
innocuous vitamin supplementation regimens (including folate, B12> and B6) effectively lower moderately elevated plasma homocysteine levels to the
normal range [l0,20,49-54}. Results of our present
study provide the rationale for a randomized, controlled trial of the effect of homocysteine-lowering
vitamin therapy on vascular disease morbidity
and mortality in hyperhomocysteinemic, elderly
individuals.
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